In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Outlook 2024 Metabolic Disorders Commercial

The Future Of Obesity

  • Analysis

Executive Summary

Novo Nordisk and Eli Lilly are duking it out in the market, but dozens of competitors are waiting in the wings. 

You may also be interested in...



Altimmune Regains Some Momentum

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.

Corporate VCs Play A Bigger Role In Hard Times

The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.

BioCardia Aims To Defy Precedent With A Cardiac Cell Therapy

Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?

Table

View full table

Topics

Related Companies

Tags:
Outlook 2024 Metabolic Disorders Commercial
Latest Headlines

Will Medicare Price Negotiation Stop Post-Approval R&D?

Medicare Price Setting And The Value Of Post-Approval R&D Spending

The New Challenge For The Architect Of Wegovy

Concerns And Hopes For Health Care Delivery In 2024

See All
UsernamePublicRestriction

Register

IV148617

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By